The company aims to enable the cost-effective, reliable, and rapid development of new cell therapies.Stem cells unlock a range of treatment possibilities that have not previously been available to patients. While current treatment options rely on the
CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of novel cell therapies, has announced a £7.6 million seed round.
CellVoyant secures £7 6 million AI stem cell boost pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.